Therapeutic effect of mirtazapine with venlafaxine in the treatment of tension headaches

Comparative study of the therapeutic effect of mirtazapine with venlafaxine in the treatment of tension headaches

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20210410050915N1

Enrollment

130

Registered

2021-05-12

Start date

2021-05-22

Completion date

Unknown

Last updated

2021-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tension headaches. Cluster headaches and other trigeminal autonomic cephalgias (TAC)

Interventions

Intervention 1: Intervention group: Mirtazapine 15 mg daily. Intervention 2: Control group: Venlafaxine 37.5 g daily.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients for whom the diagnosis of tension headache has been confirmed by a neurologist. The patient has the consent to participate in the study.

Exclusion criteria

Exclusion criteria: Patients who do not have the consent to enter the study. Patients with chronic physical diseases such as kidney-liver, heart, lung, cancer, autoimmune, etc. and mental problems. A specialist doctor has diagnosed them with other headaches such as migraines.

Design outcomes

Primary

Measure	Time frame
Reduce pain. Timepoint: Before the intervention, three months and six months later. Method of measurement: Comparison of therapeutic effect of mirtazapine with venlafaxine.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAhmad Chitsaz

Esfahan University of Medical Sciences

ahmadchitsaz@med.mui.ac.ir+98 913 310 1971

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026